Mylan, Matrix Join Forces To Slash Prices Of AIDS, TB Drugs
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Mylan and Pfizer plan to drastically lower prices for second-line HIV/AIDS and tuberculosis drugs used in developing countries following an agreement with the Clinton Foundation